G

ood morning, everyone. Damian Garde here, in for Ed Silverman, with your roundup of tidbits from the world of pharma. So begins another week, with the attendant meetings, deadlines, and interminable conference calls. For those of you soon staring down a blizzard, stay warm out there, and do drop us a line if you hear something interesting.

Dr. Scott Gottlieb is the man on deck to lead President Donald Trump’s FDA, a long-suspected bit of news that was made official Friday night. Gottlieb was the establishment choice among the cast of characters under consideration, and he comes to the agency with a mandate to speed up the drug approval process. The pick drew bipartisan praise and was widely celebrated by the drug industry, but Gottlieb’s close ties to pharma could be a drag on Senate confirmation, as was the case for his predecessor.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy